We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+29.17%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$836M
AUM Growth
+$210M
Cap. Flow
+$82.3M
Cap. Flow %
9.85%
Top 10 Hldgs %
42.54%
Holding
96
New
9
Increased
7
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$15.2M
2
CLLS
Cellectis
CLLS
+$13.9M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.6M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.74M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$9.21M

Top Sells

Rank Stock Value
1
RGLS
Regulus Therapeutics
RGLS
+$7.23M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$5.84M
3
ARRY
Array Biopharma Inc
ARRY
+$3.88M
4
CRIS icon
Curis
CRIS
+$3.59M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$3.17M

Sector Composition

Rank Sector Weight
1 Healthcare 91.58%
2 Miscellaneous 8.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
51
Iovance Biotherapeutics
IOVA
$4.48B
$3.86M 0.46%
499,815
– –
IMDZ
52
DELISTED
Immune Design Corp.
IMDZ
$3.79M 0.45%
189,000
– –
ZYNE
53
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$3.59M 0.43%
356,600
– –
CRIS icon
54
Curis
CRIS
$2.76M
$3.38M 0.4%
581
-735
-56% -$3.59M
EPRS
55
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$2.77M 0.33%
896,600
– –
APTO
56
DELISTED
Aptose Biosciences, Inc.
APTO
$2.74M 0.33%
2,404
– –
BPMC
57
DELISTED
Blueprint Medicines
BPMC
$2.63M 0.32%
100,000
– –
RGNX icon
58
Regenxbio
RGNX
$519M
$2.6M 0.31%
156,741
– –
TPST icon
59
Tempest Therapeutics
TPST
$20.2M
$2.46M 0.29%
86
– –
GNVC
60
DELISTED
GenVec, Inc.
GNVC
$2.16M 0.26%
117,624
– –
NGNE icon
61
Neurogene
NGNE
$677M
$1.87M 0.22%
7,500
– –
AGRX
62
DELISTED
Agile Therapeutics
AGRX
$1.78M 0.21%
91
– –
CBIO
63
Crescent Biopharma
CBIO
$655M
$1.62M 0.19%
2,836
-1,754
-38% -$1.16M
FOLD
64
DELISTED
Amicus Therapeutics
FOLD
$1.46M 0.17%
150,000
– –
AVEO
65
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.37M 0.16%
108,772
-50,000
-31% -$594K
ASND icon
66
Ascendis Pharma A/S
ASND
$16.3B
$1.13M 0.13%
61,500
– –
CFRX
67
DELISTED
ContraFect Corporation
CFRX
$1.11M 0.13%
293
– –
VCYT icon
68
Veracyte
VCYT
$3.2B
$994K 0.12%
137,990
– –
HTGM
69
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$876K 0.1%
1,117
– –
PVCT
70
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$858K 0.1%
2,200,000
– –
SRRA
71
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$799K 0.1%
1,329
– –
BITI
72
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$718K 0.09%
50,000
– –
NEOS
73
DELISTED
Neos Therapeutics, Inc
NEOS
$716K 0.09%
50,000
– –
NSTG
74
DELISTED
NanoString Technologies, Inc.
NSTG
$588K 0.07%
40,000
– –
PVCT.WS
75
DELISTED
PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
$550K 0.07%
2,200,000
– –
1 2
3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Cormorant Asset Management held 96 positions worth $836M, up 34% from $626M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Cormorant Asset Management deployed $82.3M of net new capital in Q4 2015, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was MacroGenics: 500,000 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regulus Therapeutics, an estimated $7.23M trimmed.

  • Cormorant Asset Management's largest Q4 2015 buy was MacroGenics: 500,000 shares worth $15.5M.
  • Cormorant Asset Management added most to Cellectis in Q4 2015, an estimated $13.9M increase.
  • Cormorant Asset Management's biggest Q4 2015 reduction was Regulus Therapeutics, cutting an estimated $7.23M.
  • Cormorant Asset Management fully exited Array Biopharma Inc in Q4 2015, selling an estimated $3.88M.
  • Cormorant Asset Management's ten largest holdings make up 43% of its $836M portfolio in Q4 2015.
  • Cormorant Asset Management opened 9 new positions and closed 14 in Q4 2015.
  • Cormorant Asset Management's portfolio value rose 34% quarter-over-quarter to $836M.

Based on Cormorant Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.